Viridian Therapeutics (VRDN) Stock Posts Double-Digit Growth Year-on-Year

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds.  The stock posted a 12.72% increment from a year ago, and a 51.76% year-to-date decline. Based on consensus, Wall Street analysts have an average price target of $32.33 for Viridian Therapeutics.

In March, Viridian Therapeutics announced positive topline data from the elegrobart REVEAL-1 phase 3 clinical trial in patients with active thyroid eye disease (TED). Elegrobart is a subcutaneously delivered, half-life-extended monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R). REVEAL-1 evaluated two dosing regimens, every four weeks (Q4W) and every eight weeks (Q8W), compared with placebo.

Viridian Therapeutics President and Chief Executive Officer Steve Mahoney expressed excitement in reporting the results. In a statement, he said:

“REVEAL-1 met its primary endpoint with high statistical significance. Elegrobart treatment drove robust proptosis responses in a treatment regimen comprised of as few as three subcutaneous doses. Further, in the Q4W arm, we saw clinically meaningful diplopia responses and diplopia resolution. Currently, the only marketed treatment for TED requires eight intravenous infusions and, despite low market penetration, annualized in 2025 to approximately $2B in revenues. We believe there is a significant opportunity with subcutaneous elegrobart in TED, including the potential to expand the market as an at-home and self-administered treatment option, if approved.”

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for patients with serious and rare diseases. The company’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for validated drug targets and disease-driving mechanisms in autoimmune and rare diseases.

READ NEXT: 10 Best Data Center Stocks to Buy for the Long Term and 8 Must-Buy Small Cap Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.